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Abstract
Background: The key elements in tuberculosis (TB) control are to cure the individual patient, interrupt
transmission of TB to others and prevent the tubercle bacilli from becoming drug resistant. Incomplete
treatment may result in excretion of bacteria that may also acquire drug resistance and cause increased
morbidity and mortality. Treatment outcome results serves as a tool to control the quality of TB
treatment provided by the health care system. The aims of this study were to evaluate the treatment
outcome for new cases of culture positive pulmonary TB registered in Norway during the period 1996–
2002 and to identify factors associated with non-successful treatment.
Methods: This was a register-based cohort study. Treatment outcome was assessed according to sex,
birthplace, age group, isoniazid (INH) susceptibility, mode of detection and treatment periods (1996–1997,
1998–1999 and 2000–2002). Logistic regression was also used to estimate the odds ratio for treatment
success vs. non-success with 95% confidence interval (CI), taking the above variables into account.
Results: Among the 655 patients included, the total treatment success rate was 83% (95% CI 80%–86%).
The success rates for those born in Norway and abroad were 79% (95% CI 74%–84%) and 86% (95% CI
83%–89%) respectively. There was no difference in success rates by sex and treatment periods. Twenty-
two patients (3%) defaulted treatment, 58 (9%) died and 26 (4%) transferred out. The default rate was
higher among foreign-born and male patients, whereas almost all who died were born in Norway. The
majority of the transferred out group left the country, but seven were expelled from the country. In the
multivariate analysis, only high age and initial INH resistance remained as significant risk factors for non-
successful treatment.
Conclusion: Although the TB treatment success rate in Norway has increased compared to previous
studies and although it has reached a reasonable target for treatment outcome in low-incidence countries,
the total success rate for 1996–2002 was still slightly below the WHO target of success rate of 85%. Early
diagnosis of TB in elderly patients to reduce the death rate, abstaining from expulsion of patients on
treatment and further measures to prevent default could improve the success rate further.
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Background
The key elements in tuberculosis (TB) control are to detect
the disease as early as possible and to ensure that those
diagnosed complete their treatment and get cured. The
World Health Organization (WHO) target for treatment
success is 85 percent of all detected smear-positive cases
[1]. Even where free medication is available, many
patients are not successfully treated [2,3]. Main reasons
for non-success are death (while on treatment or before
start of treatment) and loss to follow-up. Incomplete
treatment may result in prolonged excretion of bacteria
that may also acquire drug resistance, cause transmission
of disease and lead to increased morbidity and mortality
[4].
Norway has about 4.5 million inhabitants, with foreign-
born residents comprising 6.9% of the total population in
2002. The proportion of TB cases from foreign-born resi-
dents has increased from 19 % in 1986 to 76 % in 2002
[5]. However, the total number of cases has remained rel-
atively stable. The reporting of treatment outcome for all
TB cases has been obligatory since 1996. A study on treat-
ment outcome for culture positive pulmonary TB in Nor-
way in 1995 showed a high death rate and a high rate of
loss to follow-up. Only 76% of patients who were
included in that study completed treatment [6]. While the
incidence rate of TB is low in Norway compared to most
countries in the world, challenges still remain in achieving
the WHO target for treatment success. However, there are
some problems with the WHO definition of success rate
and other measures have been proposed. A working group
from the WHO, the International Union Against Tubercu-
losis and Lung Disease (IUATLD) and the Royal Nether-
lands Tuberculosis Association (KNCV) have defined a
reasonable target for treatment outcome in low-incidence
countries as to reduce the proportion of patients with a
potentially bacteriologically unsuccessful outcome (fail-
ure, default, transfer) to less than 10% [7].
The aims of this study were to evaluate the treatment out-
come for new culture positive pulmonary TB cases regis-
tered in Norway during the period 1996–2002, and to
identify factors associated with non-successful treatment.
Methods
Setting and study population
This was a register-based cohort study. In Norway, there is
compulsory nominative notification of all TB cases
directly to the National TB Registry. Both suspected and
confirmed cases have to be reported by clinicians. Labora-
tories of clinical microbiology are also required to report
all isolates of Mycobacteria. A total of 25 microbiological
laboratories isolate M. tuberculosis from patient samples.
The laboratory at the Norwegian Institute of Public Health
functions as a national reference laboratory for TB. The
Pharmacy at the National Hospital is the only pharmacy
distributing drugs for TB treatment, and TB prescriptions
are compared with the National TB Registry in order to
identify cases that may not have been notified. The notifi-
cation is therefore considered to be quite complete [8].
There is also compulsory notification of all treatment out-
comes to the Registry. Nine months after treatment start,
the Register sends a special form to the clinician in charge
to be filled out with details of the treatment outcome.
In this study, we included all new cases with culture posi-
tive pulmonary TB notified during 1996–2002. The spu-
tum smear results were not recorded or reported for all
cases, especially in the first years of the study period. We
therefore based our analysis of treatment outcome on new
cases with culture positive pulmonary TB.
The mode of detection was determined by information on
the notification form. Data on susceptibility to TB drugs
was obtained from the notification forms and laboratory
reports. In addition to the information in the TB Registry,
we used data from the Cause of Death Registry at Statistics
Norway to determine the cause of death for those who
died under treatment or before start of treatment.
Recommended regime for TB treatment in the study
period consisted of isoniazid (INH), rifampicin and
pyrazinamide in the intensive phase (two months).
Ethambutol was added when resistance was suspected
such as in foreign-born patients and in previously treated
patients. The continuation phase consisted of four
months with INH and rifampicin [9].
Directly Observed Therapy (DOT) was used before 2003
on an individual basis. However, we have no data to show
how many patients in this study received DOT.
Definition
The treatment outcome was divided into six categories
according to WHO guidelines, with some modifications
[10]. These categories were: cured (finished treatment with
negative bacteriology result at the end of treatment), com-
pleted treatment (finished treatment, but without bacteriol-
ogy result at the end of treatment), failure  (remaining
smear/ culture positive at five months despite correct
intake of medication), defaulted treatment (patients who
interrupted their treatment for two consecutive months or
more after registration), died (patients who died due to TB
or other cause before or during treatment), transferred out
(patients whose treatment results are unknown due to
emigration before or during treatment). Patients who
changed treatment due to multi-drug resistant TB (MDR-
TB), i.e. resistance to both INH and rifampicin, were also
defined as failures [11].BMC Public Health 2005, 5:14 http://www.biomedcentral.com/1471-2458/5/14
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Treatment success was defined as the sum of the cases that
were cured and that completed treatment.
The proportion of patients with a potentially bacteriolog-
ically unsuccessful outcome (failure, default, transfer) was
also calculated [7].
Statistical analysis
We used the statistical package SPSS, version 11.0 for data
analysis. To estimate the odds ratio for treatment outcome
(success vs. non-success), logistic regression analysis was
used. Confidence interval (CI) for the odds ratio has also
been given. Variables such as sex, birthplace, age group,
INH susceptibility, mode of detection and treatment peri-
ods (1996–1997, 1998–1999 and 2000–2002) were
entered into both univariate and multivariate logistic
regression model. P values of less than 0.05 were consid-
ered statistically significant.
Results
Six hundred and fifty-five new culture positive pulmonary
TB patients were included in the study (table 1). Of these,
397 patients (61%) were foreign-born. Three hundred
and twenty three patients (49%) were cured and 221
patients (34%) completed treatment. This gives a treat-
ment success rate of 83% (95% CI 80%–86%). The treat-
ment success rates for women and men were 86% (95%
CI 82%–90%) and 81% (95% CI 77%–85%) respectively.
For those born in Norway and abroad, the rates were 79%
(95% CI 74%–84%) and 86% (95% CI 83%–89%)
respectively. The rates for the treatment periods 1996–
1997, 1998–1999 and 2000–2002 were 83% (95% CI
77%–89%), 82% (95% CI 76%–88%) and 84% (95% CI
80%–88%) respectively.
In our study, the proportion of patients with a potentially
bacteriologically unsuccessful outcome (failure, default,
transfer) was 8%.
The average duration of residence in Norway for foreign-
born patients at TB registration was 3.8 (range 1–31)
years. There were no differences in the treatment success
rates for those who had lived in Norway for less than three
years and for those who had stayed longer than three
years.
Among the 22 patients who defaulted treatment (3%)
(table 1), four had MDR-TB and three additional patients
had isolated INH resistant strains at the start of the treat-
Table 1: Number of new culture positive pulmonary tuberculosis patients by patient characteristics and treatment outcome, Norway, 
1996–2002
Cured Completed 
treatment
Failure* Defaulted 
treatment
Died Transferred 
Out†
Total
Sex
Women 144 90 2 7 17 11 271
Men 179 131 3 15 41 15 384
Birthplace
Norway 119 84 1 5 49 0 258
Abroad 204 137 4 17 9 26 397
Age group (yrs)
0 – 1 4 6 1 9 0100 2 6
15–39 170 105 3 13 4 14 309
4 0 – 6 4 5 94 5 2 4 1 11 0 1 3 1
6 5 + 8 8 5 20 44 32 1 8 9
INH-resistance‡
No 295 210 0 15 53 22 595
Y e s 2 1 1 0 5724 4 9
Mode of detection# (due to symptoms)
Yes 221 154 3 16 47 12 453
No 100 67 2 6 11 13 199
Treatment periods
1996–1997 67 48 0 3 19 2 139
1998–1999 83 58 1 7 20 3 172
2000–2002 173 115 4 12 19 21 344
*All patients are MDR-TB patients
†All patients have left the country
‡Information for INH susceptibility was available for 98.3% of the patients
#Information for mode of detection was available for 99.5% of the patientsBMC Public Health 2005, 5:14 http://www.biomedcentral.com/1471-2458/5/14
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ment. The default rate was higher among foreign-born
and male patients.
There were 26 patients (4%) who were transferred out
(table 1). Of these, 21 were reported in 2000–2002. All of
them have left the country. Twenty-two were on treatment
when they left the country and four had not started treat-
ment. Among the 26, seven were expelled from the coun-
try. Six of these were on treatment and one had not started
treatment at the time of expulsion. For those who left the
country while on treatment, the average duration of treat-
ment was 78 days. Twelve of them had treatment only for
two months or less. Of the 26 patients who were trans-
ferred out, three had isolated INH resistant strains and
one had MDR-TB when they left the country.
Altogether 58 patients (9%) died, 19 (3%) before treat-
ment start and 39 (6%) while on treatment. Of those who
died before treatment start, four were diagnosed after
death at autopsy. Eighty four percent of those who died
were born in Norway. The median age for all who died
was 80 years. For those who died before treatment start,
the median age was 71 years. For those who died while on
treatment, the median age was 81 years and the average
duration of treatment was 67 days. Sixteen patients died
within 14 days of treatment start. For 23 patients, TB was
the primary cause of death. It was the only cause of death
for nine of those 23 patients. For further 20 patients, TB
was a contributing factor to their death. Fourteen patients
died from other diseases than TB. The cause of death was
unknown for one patient (table 2).
There was no systematic registration of TB/ human immu-
nodeficiency virus (HIV) co-infection at the TB Registry.
For those who died while on treatment or before treat-
ment started, HIV disease was registered as the cause of
death for two patients (table 2).
Table 3 gives the odds ratio from logistic regression. The
effect of birthplace in the treatment success changed from
the univariate to the multivariate analysis. Patients who
were born abroad had higher odds of success in the uni-
variate analysis, but this changed to lower odds for success
in the multivariate analysis. This is due to a strong con-
founding effect of age. The effect of age was distinct and
graded, slightly stronger in the multivariate analysis. Both
in the univariate and multivariate analysis, the odds for
success were lower for those with INH resistant strains
than for those with INH susceptible strains.
Susceptibility testing for the main TB drugs was done in
most of the patients. However, susceptibility testing for
streptomycin was done for fewer patients than other main
TB drugs. Resistance to INH and streptomycin was most
common, and resistance was frequent among foreign-
born patients. Of those with MDR-TB, two were born in
Norway and eight abroad.
Table 2:  Primary causes of death among new culture positive pulmonary tuberculosis patients, Norway, 1996–2002*
Tuberculosis mentioned on the death certificate
Yes (N = 43) No (N = 14))
Tuberculosis (N = 23)† Heart failure (N = 1)
Acute myocardial infarction (N = 3) Unspecified HIV disease (N = 1)
Heart failure (N = 2) Unspecified non-Hodgkin's lymphoma (N = 1)
Unspecified cardiac arrest (N = 1) Amyloidosis (N = 1)
Stroke, not specified as haemorrhage or infarction (N = 2) Multiple myeloma (N = 1)
Chronic ishaemic heart disease (N = 2) Mental and behavioural disorders due to use of opoids (N = 1)
Paroxysmal tachycardia (N = 1) Mental and behavioural disorders due to multiple drug use and use of 
other psychoactive substances (N = 1)
Other chronic obstructive pulmonary disease (N = 1) Malignant neoplasm of bronchus and lung (N = 5)
Unspecified respiratory failure (N = 1) Liver cell carcinoma (N = 1)
Unspecified HIV disease (N = 1) Other ill-defined and specified causes of mortality (N = 1)
Other acute viral hepatitis (N = 1)
Unspecified sepsis (N = 1)
Unspecified non-Hodgkin's lymphoma (N = 1)
Spinal muscular atrophy and related syndromes (N = 1)
Malignant neoplasm of breast (N = 1)
Malignant neoplasm of bronchus and lung (N = 1)
*The cause of death was unknown for one patient
†Including respiratory and miliary tuberculosisBMC Public Health 2005, 5:14 http://www.biomedcentral.com/1471-2458/5/14
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Of the 655 patients included in this study, 453 were
detected through passive case finding (due to their symp-
toms). Another 101 patients were discovered through the
immigration TB screening program. A total of 52 patients
were detected through following ups of close contacts of
identified infectious cases (22 cases) and of previous
abnormal mass miniature radiology (MMR) (32 cases).
The remainder was discovered through other screening
programs. No information on mode of detection was
available for three patients.
Discussion
In our study, the total treatment success rate for new cul-
ture positive pulmonary TB for the period 1996–2002 was
83%. This is close to the WHO target of success rate of
85% of all smear positive cases. However, subgroups of
patients contributing to low success rate warrant special
attention such as those who defaulted treatment, those
who were transferred out and those who died. The first
two subgroups mainly comprise patients who were born
abroad and the last subgroup mainly comprises patients
who were born in Norway. Despite these problems, Nor-
way has reached the reasonable target for treatment out-
come in low-incidence countries [7].
Our study shows a default rate of 3%. Higher default rates
have been described in other studies such as Vaud County,
Switzerland (16%) [2], Hamburg, Germany (10%) [12],
and Sweden (7%) [3]. Although the default rate in Nor-
way is lower than in these countries, some of the patients
who defaulted treatment, including patients with MDR-
TB, have been the cause of small on-going outbreaks [13].
Default can constitute a major public health problem.
Although incomplete treatment can prevent patients from
dying from TB, the patients may remain infectious and
even develop MDR-TB. It is therefore worrying that several
patients in our study who defaulted treatment had iso-
lated INH resistant strains or MDR-TB prior to treatment.
Language problems, lack of understanding of the patients'
cultural background, lack of communication between
primary health care and hospitals, frequent change of
address and stigma related to TB might be some of the
reasons for defaulting. DOT was used on an individual
basis during the study period, especially when an
increased risk of non-adherence was suspected, but it
became mandatory in Norway from 2003 according to the
new TB regulations [14]. Adoption of this strategy will
hopefully improve treatment adherence further.
In the transferred out group, the majority of patients left
the country on their own initiative, but seven were
Table 3: Odds ratio (OR) for treatment success vs. non-success among new culture positive pulmonary tuberculosis patients notified in 
Norway, 1996–2002
Treatment Success Univariate Multivariate*
Yes No OR 95% CI OR 95% CI
Sex
Women 234 37 ref. ref. ref. ref.
Men 310 74 0.7 04–1.0 0.7 0.4–1.1
Birthplace
Norway 203 55 ref. ref. ref. ref.
Abroad 341 56 1.7 1.1–2.5 0.7 0.3–1.3
Age group (yrs)
0–14 25 1 8.7 1.2–65.6 11.8 1.5–92.6
15–39 275 34 2.8 1.7–4.6 4.8 2.3–10.0
40–64 104 27 1.3 0.8–2.3 2.0 1.1–3.9
65+ 140 49 ref. ref. ref. ref.
INH-resistance
No 505 90 ref. ref. ref. ref.
Yes 31 18 0.3 0.2–0.6 0.2 0.1–0.4
Mode of detection (due to symptoms)
Yes 375 78 ref. ref. ref. ref.
No 167 32 1.1 0.7–1.7 1.1 0.7–1.7
Treatment periods
1996–1997 115 24 0.9 0.6–1.6 1.2 0.7–2.2
1998–1999 141 31 0.9 0.5–1.4 0.9 0.5–1.5
2000–2002 288 56 ref. ref. ref. ref.
*In the multivariate analysis, all variables in the univariate analysis were consideredBMC Public Health 2005, 5:14 http://www.biomedcentral.com/1471-2458/5/14
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expelled. Most of the patients who left the country were
on treatment, but we do not have information about their
treatment outcome. It is worrying that some of the
patients who were expelled moved to countries with polit-
ical unrest and poorly functioning TB programs. In this
group three patients already had isolated INH resistant
strains and one had MDR-TB. Expelling patients with TB
before completion of treatment is unfortunate, unless it
can be guaranteed that adequate treatment will be pro-
vided elsewhere. Efforts should be made to ensure the
continuity of treatment for patients who move out of the
country and, if possible, to allow them to start and com-
plete their treatment, even if they have to leave the coun-
try later. The Netherlands have adopted a system where
patients are not expelled from the country as long as they
are on treatment. According to the new Norwegian man-
ual for TB control and prevention [11], health personnel
should encourage patients who are at risk to be expelled
from the country to inform the Norwegian Directorate of
Immigration through their legal representatives about
their disease, and they may then be allowed to stay until
treatment is completed. However, we believe there is a
need for more awareness among health personnel, immi-
gration authorities, the police and the legal representa-
tives of the patients about this possibility.
The death rate in our study was 9%. Other studies from
low TB incidence regions of the world showed death rates
among TB patients of 24%, 14% and 6% in Baltimore
City, USA [15], Vaud County, Switzerland [2] and Ham-
burg, Germany [12] respectively. Common for these stud-
ies and our study is that most patients who died were old,
and many of them also had other illnesses. But if we only
include only patients who started treatment, the actual
death rate for our study was 6%. When considering the
treatment outcome of TB, many studies including ours,
include patients who never started treatment. This might
seem contradictory, but it is an important issue that shows
a deficiency in TB control. This is also in line with the rec-
ommendations of a working group of the WHO and the
European Region of the IUATLD for uniform reporting by
cohort analysis of treatment outcome in TB patients [16].
It has been suggested that acceptable treatment success
rates need to be revised under such circumstances. It is dif-
ficult to know to what extent the death of the nine patients
whose only cause of death was TB could have been pre-
vented. Diagnosis of pulmonary TB can be especially dif-
ficult in older patients with co-existing illness. In one
study, it was suggested that treatment of latent TB in such
high risk elderly patients should be a high priority
although advanced age is a relative contraindication [17].
Other studies recommend the start of anti-TB treatment
on suspicion whilst awaiting results of diagnostic tests in
elderly patients, provided there is no other obvious cause
of their illness [18,19]. This makes sense as our study
shows that 19 patients died before treatment start and
four of them were diagnosed at autopsy. Two studies from
Canada [20] and former Yugoslavia [21] have concluded
that delay in diagnosis of TB was the main factor contrib-
uting to death from TB. Delay in diagnosis is outside the
scope of this study. But autopsy rates in Norway are low
[18] and therefore it is likely that there is under-diagnosis
of deaths due to TB.
As indicated in the results section, TB/HIV co-infection is
not a common cause of death for TB patients in Norway
as most of the patients born in Norway were elderly per-
sons with low risk of HIV and most foreign-born patients
were from countries with low levels of HIV infection [22].
Therefore, we believe that it had a minor impact on the
treatment outcome.
In the logistic regression model, increasing age and INH
resistance were significant risk factors for non-successful
treatment. We expected to find that age played a role,
since old age in itself will contribute towards higher mor-
tality, partly through co-existing illness. INH is a powerful
bactericidal drug and resistance to the drug might reduce
the effectiveness of standard short-course treatment [23].
Treatment was fairly standardized even in the previous TB
manual from 1996: Four drugs to all foreign-born and to
all previously treated TB patients and three drugs to
patients born in Norway who were not likely to have been
infected with drug resistant strains abroad. However, an
analysis made by the National TB register in 1999 showed
that only 75% of foreign-born patients received four drugs
at the start of their treatment (Heldal E, personal commu-
nication, National TB Registry of Norway).
Conclusion
Although the TB treatment success rate in Norway has
increased compared to previous studies and although it
has reached a reasonable target for treatment outcome in
low-incidence countries, the total success rate for 1996–
2002 was still slightly below the WHO target of success
rate of 85%. Early diagnosis of TB in elderly patients to
reduce the death rate, abstaining from expulsion of
patients on treatment and further measures to prevent
default could improve the success rate further.
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